• May 28, 2021

DiaVacs Immunotherapy

Cell-Based Type 1 Diabetes and SARS-COV2

diavacs
Lenti Medium rna

Inflammation and cancer.

Studies on transformation of Escherichia coli with plasmids.

Factors that affect the probability of genetic transformation of Escherichia coli by plasmids have been evaluated. A set of conditions is described under which about one in every 400 plasmid molecules produces a transformed cell. These conditions include cell growth in medium containing elevated levels of Mg2+, and incubation of the cells at 0 degrees C in a solution of Mn2+, Ca2+, Rb+ or K+, dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III). Transformation efficiency declines linearly with increasing plasmid size. Relaxed and supercoiled plasmids transform with similar probabilities. Non-transforming DNAs compete consistent with mass. No significant variation is observed between competing DNAs of different source, complexity, length or form. Competition with both transforming and non-transforming plasmids indicates that each cell is capable of taking up many DNA molecules, and that the establishment of a transformation event is neither helped nor hindered significantly by the presence of multiple plasmids.

Inflammation and cancer.

Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
diavacs
diavacs

Improved survival with ipilimumab in patients with metastatic melanoma.

BACKGROUND
An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab–which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response–administered with or without a glycoprotein 100 (gp100) peptide vaccine was compared with gp100 alone in patients with previously treated metastatic melanoma.
METHODS
A total of 676 HLA-A*0201-positive patients with unresectable stage III or IV melanoma, whose disease had progressed while they were receiving therapy for metastatic disease, were randomly assigned, in a 3:1:1 ratio, to receive ipilimumab plus gp100 (403 patients), ipilimumab alone (137), or gp100 alone (136). Ipilimumab, at a dose of 3 mg per kilogram of body weight, was administered with or without gp100 every 3 weeks for up to four treatments (induction). Eligible patients could receive reinduction therapy. The primary end point was overall survival.
RESULTS
The median overall survival was 10.0 months among patients receiving ipilimumab plus gp100, as compared with 6.4 months among patients receiving gp100 alone (hazard ratio for death, 0.68; P<0.001). The median overall survival with ipilimumab alone was 10.1 months (hazard ratio for death in the comparison with gp100 alone, 0.66; P=0.003). No difference in overall survival was detected between the ipilimumab groups (hazard ratio with ipilimumab plus gp100, 1.04; P=0.76). Grade 3 or 4 immune-related adverse events occurred in 10 to 15% of patients treated with ipilimumab and in 3% treated with gp100 alone. There were 14 deaths related to the study drugs (2.1%), and 7 were associated with immune-related adverse events.
CONCLUSIONS
Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse events can be severe, long-lasting, or both, but most are reversible with appropriate treatment. (Funded by Medarex and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00094653.)

Understanding the Warburg effect: the metabolic requirements of cell proliferation.

In contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation to generate the energy needed for cellular processes, most cancer cells instead rely on aerobic glycolysis, a phenomenon termed “the Warburg effect.” Aerobic glycolysis is an inefficient way to generate adenosine 5′-triphosphate (ATP), however, and the advantage it confers to cancer cells has been unclear. Here we propose that the metabolism of cancer cells, and indeed all proliferating cells, is adapted to facilitate the uptake and incorporation of nutrients into the biomass (e.g., nucleotides, amino acids, and lipids) needed to produce a new cell. Supporting this idea are recent studies showing that (i) several signaling pathways implicated in cell proliferation also regulate metabolic pathways that incorporate nutrients into biomass; and that (ii) certain cancer-associated mutations enable cancer cells to acquire and metabolize nutrients in a manner conducive to proliferation rather than efficient ATP production. A better understanding of the mechanistic links between cellular metabolism and growth control may ultimately lead to better treatments for human cancer.
Human blastocyst-derived, pluripotent cell lines are described that have normal karyotypes, express high levels of telomerase activity, and express cell surface markers that characterize primate embryonic stem cells but do not characterize other early lineages. After undifferentiated proliferation in vitro for 4 to 5 months, these cells still maintained the developmental potential to form trophoblast and derivatives of all three embryonic germ layers, including gut epithelium (endoderm); cartilage, bone, smooth muscle, and striated muscle (mesoderm); and neural epithelium, embryonic ganglia, and stratified squamous epithelium (ectoderm). These cell lines should be useful in human developmental biology, drug discovery, and transplantation medicine.

MACCONKEY AGAR W/O CRYSTAL VIOLET
M13-108-10kg 10 kg Ask for price

MACCONKEY AGAR W/O CRYSTAL VIOLET
M13-108-2kg 2kg Ask for price

MACCONKEY AGAR W/O CRYSTAL VIOLET
M13-108-500g 500 g Ask for price

MACCONKEY BROTH
M13-111-10kg 10 kg
EUR 997

MACCONKEY BROTH
M13-111-2Kg 2 Kg
EUR 256

MACCONKEY BROTH
M13-111-500g 500 g
EUR 106

BCYE AGAR (LEGIONELLA AGAR)
B02-103-10kg 10 kg
EUR 50

BCYE AGAR (LEGIONELLA AGAR)
B02-103-2Kg 2 Kg
EUR 757

BCYE AGAR (LEGIONELLA AGAR)
B02-103-500g 500 g
EUR 304

Agar D, Purified Agar
G243 100g
EUR 81.32

Agar
abx082160-500g 500 g
EUR 217

LB AGAR - LENNOX LB AGAR
L12-100-10kg 10 kg
EUR 826

LB AGAR - LENNOX LB AGAR
L12-100-2Kg 2 Kg
EUR 219

LB AGAR - LENNOX LB AGAR
L12-100-500g 500 g
EUR 96

LURIA AGAR - MILLER'S LB AGAR
L12-111-10kg 10 kg
EUR 829

LURIA AGAR - MILLER'S LB AGAR
L12-111-2Kg 2 Kg
EUR 219

LURIA AGAR - MILLER'S LB AGAR
L12-111-500g 500 g
EUR 96

BIGGY AGAR
B02-105-10kg 10 kg
EUR 1827

BIGGY AGAR
B02-105-2Kg 2 Kg
EUR 436

BIGGY AGAR
B02-105-500g 500 g
EUR 155

BRUCELLA AGAR
B02-119-10kg 10 kg
EUR 1464

BRUCELLA AGAR
B02-119-2kg 2kg
EUR 357

BRUCELLA AGAR
B02-119-500g 500 g
EUR 134

BACTERIOLOGICAL AGAR
B02-127-10kg 10 kg
EUR 930

BACTERIOLOGICAL AGAR
B02-127-2kg 2kg
EUR 244

BACTERIOLOGICAL AGAR
B02-127-500g 500 g
EUR 103

DEOXYCHOLATE AGAR
D04-104-10kg 10 kg
EUR 1319

DEOXYCHOLATE AGAR
D04-104-2kg 2kg
EUR 326

DEOXYCHOLATE AGAR
D04-104-500g 500 g
EUR 125

DRBC AGAR
D04-114-10kg 10 kg
EUR 1221

DRBC AGAR
D04-114-2Kg 2 Kg
EUR 305

DRBC AGAR
D04-114-500g 500 g
EUR 119

EUGONIC AGAR
E05-106-10kg 10 kg Ask for price

EUGONIC AGAR
E05-106-2Kg 2 Kg Ask for price

EUGONIC AGAR
E05-106-500g 500 g Ask for price

ENDO AGAR
E05-110-10kg 10 kg
EUR 2381

ENDO AGAR
E05-110-2Kg 2 Kg
EUR 557

ENDO AGAR
E05-110-500g 500 g
EUR 188

APT AGAR
A01-101-10kg 10 kg
EUR 1173

APT AGAR
A01-101-2Kg 2 Kg
EUR 294

APT AGAR
A01-101-500g 500 g
EUR 116

AGAR, BACTERIOLOGICAL
A01-102-10kg 10 kg
EUR 1684

AGAR, BACTERIOLOGICAL
A01-102-2kg 2kg
EUR 405

AGAR, BACTERIOLOGICAL
A01-102-500g 500 g
EUR 146

AGAR,NOBLE
A01-102N-10kg 10 kg
EUR 3910

AGAR,NOBLE
A01-102N-2kg 2kg
EUR 889

AGAR,NOBLE
A01-102N-500g 500 g
EUR 278

ANAEROBIC AGAR
A01-115-10kg 10 kg
EUR 2556

ANAEROBIC AGAR
A01-115-2kg 2kg
EUR 595

ANAEROBIC AGAR
A01-115-500g 500 g
EUR 198

Agar Bacteriological
abx082171-500g 500 g
EUR 578

CLED AGAR
C03-101-10kg 10 kg
EUR 1485

CLED AGAR
C03-101-2Kg 2 Kg
EUR 362

CLED AGAR
C03-101-500g 500 g
EUR 135

CLOSTRISEL AGAR
C03-110-10kg 10 kg
EUR 1033

CLOSTRISEL AGAR
C03-110-2Kg 2 Kg
EUR 264

CLOSTRISEL AGAR
C03-110-500g 500 g
EUR 108

Spectrum Agar
CP044-005 500 g Ask for price

Spectrum Agar
CP044-010 1 Kg Ask for price

Agar, Bacto
A2007-050 500g
EUR 192

Agar, Bacto
A2007-250 2.5Kg
EUR 604

Agar, Bacto
A2007-550 50Kg Ask for price

Agar (bacteriological)
A2530-2000000 2 kg
EUR 383
Description: microbiological culture mediapasses growth performance tests with known ATCC strainsWilliams, S., Slatko, B., and McCarrey, J., Laboratory Investigations in Molecular BiologyJones and Bartlett, Sudbury, MA (2006)store dry at room temperature, CAS 9002-18-0

Agar (bacteriological)
A2530-500000 500 g
EUR 142
Description: microbiological culture mediapasses growth performance tests with known ATCC strainsWilliams, S., Slatko, B., and McCarrey, J., Laboratory Investigations in Molecular BiologyJones and Bartlett, Sudbury, MA (2006)store dry at room temperature, CAS 9002-18-0

FUNGISEL AGAR
F06-103-10kg 10 kg
EUR 2744

FUNGISEL AGAR
F06-103-2Kg 2 Kg
EUR 636

FUNGISEL AGAR
F06-103-500g 500 g
EUR 209

GC AGAR
G07-100-10kg 10 kg
EUR 816

GC AGAR
G07-100-2kg 2kg
EUR 217

GC AGAR
G07-100-500g 500 g
EUR 95

LB Agar
G247 500 g
EUR 183

K- AGAR
K11-103-10kg 10 kg
EUR 1380

K- AGAR
K11-103-2kg 2kg
EUR 339

K- AGAR
K11-103-500g 500 g
EUR 129

PHENYLALANINE AGAR
P16-106-10kg 10 kg
EUR 1615

PHENYLALANINE AGAR
P16-106-2kg 2kg
EUR 390

PHENYLALANINE AGAR
P16-106-500g 500 g
EUR 142

PHENYLETHANOL AGAR
P16-107-10kg 10 kg
EUR 1256

PHENYLETHANOL AGAR
P16-107-2Kg 2 Kg
EUR 312

PHENYLETHANOL AGAR
P16-107-500g 500 g
EUR 121

PALCAM AGAR
P16-140-10kg 10 kg
EUR 1267

PALCAM AGAR
P16-140-2kg 2kg
EUR 315

PALCAM AGAR
P16-140-500g 500 g
EUR 122

OATMEAL AGAR
O15-105-10kg 10 kg
EUR 1032

OATMEAL AGAR
O15-105-2kg 2kg
EUR 263

OATMEAL AGAR
O15-105-500g 500 g
EUR 108

MALT AGAR
M13-112-10kg 10 kg
EUR 50

MALT AGAR
M13-112-2kg 2kg
EUR 50

MALT AGAR
M13-112-500g 500 g
EUR 50

MYCOLOGICAL AGAR
M13-138-10kg 10 kg Ask for price

MYCOLOGICAL AGAR
M13-138-2kg 2kg Ask for price

MYCOLOGICAL AGAR
M13-138-500g 500 g Ask for price

MYP AGAR
M13-149-10kg 10 kg
EUR 949

MYP AGAR
M13-149-2Kg 2 Kg
EUR 245
Tags:
diavacs
diavacs

Leave a Reply

Your email address will not be published. Required fields are marked *